The layout of 20 15 Sanofi in China market is quietly changing.
From 20 14 to 2020, Sanofi plans to launch 18 new products around the world, and one third of these key products are drugs related to diabetes treatment.
This undoubtedly values the vast chronic disease market in China. According to the statistics of the Ministry of Health and the National Development and Reform Commission in 20 14 years, the medical expenses of 260 million patients with chronic diseases in China at that time had reached 3 trillion.
Liang Xiaofeng, deputy director of China CDC, said that aging and urbanization are the main reasons for the sharp increase in the prevalence of chronic diseases, and the development speed of chronic diseases has been accelerating in recent two years.
"A country as big as China will have many unmet medical needs. 30% of the academic articles published in Global Biomedicine come from China, and 15% of the patents come from China, which fully shows that China has great potential. Long believes that China will soon become the second largest pharmaceutical market in the world.
In addition to research and development, these multinational pharmaceutical companies have also extended the reach of channel promotion to the Internet. On June 5438+ 10 this year, Sanofi and Health Road jointly built a mobile application platform for chronic disease management-Kangsai, which is dedicated to building communication and follow-up tools between doctors and patients based on Internet mobile technology to improve the disease management level of patients with chronic diseases; Establish a continuing education platform for county doctors, improve the awareness of standardized diagnosis and treatment at the grassroots level, help build a graded diagnosis and treatment system, and truly realize two-way referral.